evidence table

Ginkgo Cognition Randomized Trial Evidence Table

Structured evidence table for Ginkgo Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Ginkgo Cognition Randomized TrialIn addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews [].3Yang YoungSoon (2026)Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
Ginkgo Cognition Randomized TrialReal-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs [].3Yang YoungSoon (2026)Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
Ginkgo Cognition Randomized TrialAccordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point.3Yang YoungSoon (2026)Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
Ginkgo Cognition Randomized Trial1 2 Alzheimer’s disease (AD) remains the most common cause of dementia and continues to impose a major burden on patients, caregivers, and healthcare systems [].3Yang YoungSoon (2026)Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
Ginkgo Cognition Randomized TrialThese limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition.3Li Xikun (2026)Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Ginkgo Cognition Randomized TrialUnlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions.3Li Xikun (2026)Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Ginkgo Cognition Randomized TrialRhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha).3Li Xikun (2026)Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Ginkgo Cognition Randomized Trial1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally ().3Li Xikun (2026)Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
topicGinkgo Cognition Randomized Trial
claimIn addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews [].
evidence level3
citationYang YoungSoon (2026)
sourceGinkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
topicGinkgo Cognition Randomized Trial
claimReal-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs [].
evidence level3
citationYang YoungSoon (2026)
sourceGinkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
topicGinkgo Cognition Randomized Trial
claimAccordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point.
evidence level3
citationYang YoungSoon (2026)
sourceGinkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
topicGinkgo Cognition Randomized Trial
claim1 2 Alzheimer’s disease (AD) remains the most common cause of dementia and continues to impose a major burden on patients, caregivers, and healthcare systems [].
evidence level3
citationYang YoungSoon (2026)
sourceGinkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
topicGinkgo Cognition Randomized Trial
claimThese limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition.
evidence level3
citationLi Xikun (2026)
sourceRhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
topicGinkgo Cognition Randomized Trial
claimUnlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions.
evidence level3
citationLi Xikun (2026)
sourceRhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
topicGinkgo Cognition Randomized Trial
claimRhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha).
evidence level3
citationLi Xikun (2026)
sourceRhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
topicGinkgo Cognition Randomized Trial
claim1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally ().
evidence level3
citationLi Xikun (2026)
sourceRhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders

Learn next

Related evidence and supplement guides

GuideMagnesium Taurate Cognition Randomized Trial: What the Evidence SaysMagnesium Taurate Cognition Randomized Trial has 1 source documents in the current Migaku eviden...GuideCreatine Cognition Randomized Trial: What the Evidence SaysCreatine Cognition Randomized Trial has 2 source documents in the current Migaku evidence databa...GuideVitamin B1 Cognition Randomized Trial: What the Evidence SaysVitamin B1 Cognition Randomized Trial has 2 source documents in the current Migaku evidence data...GuideSulforaphane Cognition Randomized Trial: What the Evidence SaysSulforaphane Cognition Randomized Trial has 1 source documents in the current Migaku evidence da...RankingBest Nootropics for Focus & Attention: 2026 Clinical Evidence ReviewWe separate the clinical evidence from the marketing hype, ranking the most effective brain supp...RankingBest Supplements for Anxiety: Evidence-Based Rankings 2026Anxiety supplements with genuine clinical evidence include ashwagandha (strongest for chronic an...RankingBest Nootropics for Focus & Cognition: 2026 Clinical RankingsAn examination of cognitive enhancers designed to increase neurotransmitter activity, improve sy...AnswerDoes Magnesium Taurate Cognition Randomized Trial work?Magnesium Taurate Cognition Randomized Trial has evidence relevant to strength of evidence and w...

Source documents

  1. Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
  2. Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders